表紙
市場調查報告書

藥物的過量攝取:開發中產品分析

Drug Overdose - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 484622
出版日期 內容資訊 英文 79 Pages
訂單完成後即時交付
價格
藥物的過量攝取:開發中產品分析 Drug Overdose - Pipeline Review, H1 2020
出版日期: 2020年03月31日內容資訊: 英文 79 Pages
簡介

本報告提供藥物的過量攝取治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中治療藥,治療藥評估,暫停中·中止的計劃等相關資訊。

簡介

  • 調查範圍

藥物的過量攝取 - 概要

藥物的過量攝取 - 治療藥的開發

  • 開發平台概要
  • 各企業的開發平台趨勢
  • 各大學·研究機關的開發平台趨勢
  • 企業開發中的產品
  • 大學·研究機關開發中的產品

藥物的過量攝取 - 治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物的過量攝取的開發治療藥的企業

藥物的過量攝取 - 藥物簡介

藥物的過量攝取 - 暫停中的計劃

藥物的過量攝取 - 開發中止的產品

藥物的過量攝取 - 產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12056IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Overdose - Pipeline Review, H1 2020, provides an overview of the Drug Overdose (Toxicology) pipeline landscape.

Drug overdoses occur when a person takes more than the medically recommended dose of a prescription or over-the-counter drug. It can be either accidental or intentional. Symptoms include sleepiness, confusion, chest pain, seizures, abdominal pain, nausea, vomiting, and diarrhea. Risk factors include age, gender, mental illness and history of overdose. Treatment includes antidote and activated charcoal.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Overdose - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Drug Overdose (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Overdose (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Drug Overdose and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 2, 1, 3, 6, 1 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Drug Overdose (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Overdose (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Drug Overdose (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Drug Overdose (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Drug Overdose (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Drug Overdose (Toxicology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Drug Overdose (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Drug Overdose (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Drug Overdose - Overview
  • Drug Overdose - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Drug Overdose - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Drug Overdose - Companies Involved in Therapeutics Development
  • Adamis Pharmaceuticals Corp
  • Amphastar Pharmaceuticals Inc
  • Crossject SA
  • Emergent BioSolutions Inc
  • Fab'entech SA
  • Icure Pharmaceutical Inc
  • Insys Therapeutics Inc
  • iQure Pharma Inc
  • Klaria Pharma Holding AB
  • Mucodel Pharma LLC
  • Opiant Pharmaceuticals Inc
  • Orexo AB
  • PledPharma AB
  • ResQ Pharma Inc
  • Vallon Pharmaceuticals Inc
  • Worphmed Srl
  • Drug Overdose - Drug Profiles
  • Antibody for Drug Overdose, Opioid Addiction and Poisoning - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • drinabant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • iQ-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • melatonin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nalmefene - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nalmefene - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • naloxone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • naloxone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • naloxone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • naloxone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • naloxone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • naloxone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • naloxone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • naloxone hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • naloxone hydrochloride 1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • naloxone. - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OPNT-006 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • physostigmine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PP-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule for Drug Overdose and Drug Toxicity - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule for Substance Abuse and Drug Overdose - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Alzheimer's Disease and Drug Overdose - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine for Drug Overdose - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drug Overdose - Dormant Projects
  • Drug Overdose - Discontinued Products
  • Drug Overdose - Product Development Milestones
  • Featured News & Press Releases
  • Dec 12, 2019: Opiant Pharmaceuticals announces contract extension of second tranche of approximately $2.4 million from Biomedical Advanced Research and Development Authority for development of OPNT003, Nasal Nalmefene, for the treatment of Opioid Overdose
  • Aug 07, 2019: Northwest Territories makes NARCAN (naloxone) nasal spray available to all residents for free of charge in response to the opioid crisis
  • Jul 03, 2019: FDA accepts new drug application for insys therapeutics naloxone nasal spray for the emergency treatment of known or suspected opioid overdose
  • Apr 08, 2019: Opiant Pharmaceuticals announces publication of clinical pharmacokinetic data supporting potential of OPNT003, nasal nalmefene, for treatment of synthetic opioid overdose
  • Apr 01, 2019: Study finds vast differences in ease-of-use for Naloxone delivery methods
  • Apr 01, 2019: Opiant Pharmaceuticals announces award of second tranche of approximately $3.0 million from National Institutes of Health Grant for development of OPNT003, nasal nalmefene, for treatment of opioid overdose
  • Mar 25, 2019: INSYS Therapeutics to present poster of pharmacokinetic study of Naloxone novel nasal spray at The College on Problems of Drug Dependence Annual Scientific Meeting
  • Jan 31, 2019: Aladote's data has been selected for presentation at The International Liver Congress
  • Jan 07, 2019: Positive results from human PK study assessing Orexo's new intranasal Naloxone formulations for opioid overdose reversal
  • Dec 24, 2018: Opiant Pharmaceuticals announces FDA Orange Book Listing for the new NARCAN Nasal Spray patent
  • Dec 18, 2018: INSYS Therapeutics announces participation at FDA Advisory Committee Meeting Addressing the Co-Prescribing of Naloxone
  • Dec 17, 2018: INSYS Therapeutics provides updates on strategic alterative review process and its pipeline product Naloxone
  • Nov 01, 2018: INSYS Therapeutics announces results of PK study assessing proprietary intranasal Naloxone formulations versus intramuscular and intravenous Naloxone for Opioid Overdose
  • Oct 24, 2018: Emergent BioSolutions to offer all public libraries and YMCAs in the U.S. free opioid awareness education and NARCAN (naloxone HCl) Nasal Spray
  • Oct 22, 2018: Opiant Pharmaceuticals to Participate in Opioid Panel at the BARDA Industry Day
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Drug Overdose, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • 1Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Drug Overdose - Pipeline by Adamis Pharmaceuticals Corp, H1 2020
  • Drug Overdose - Pipeline by Amphastar Pharmaceuticals Inc, H1 2020
  • Drug Overdose - Pipeline by Crossject SA, H1 2020
  • Drug Overdose - Pipeline by Emergent BioSolutions Inc, H1 2020
  • Drug Overdose - Pipeline by Fab'entech SA, H1 2020
  • Drug Overdose - Pipeline by Icure Pharmaceutical Inc, H1 2020
  • Drug Overdose - Pipeline by Insys Therapeutics Inc, H1 2020
  • Drug Overdose - Pipeline by iQure Pharma Inc, H1 2020
  • Drug Overdose - Pipeline by Klaria Pharma Holding AB, H1 2020
  • Drug Overdose - Pipeline by Mucodel Pharma LLC, H1 2020
  • Drug Overdose - Pipeline by Opiant Pharmaceuticals Inc, H1 2020
  • Drug Overdose - Pipeline by Orexo AB, H1 2020
  • Drug Overdose - Pipeline by PledPharma AB, H1 2020
  • Drug Overdose - Pipeline by ResQ Pharma Inc, H1 2020
  • Drug Overdose - Pipeline by Vallon Pharmaceuticals Inc, H1 2020
  • Drug Overdose - Pipeline by Worphmed Srl, H1 2020
  • Drug Overdose - Dormant Projects, H1 2020
  • Drug Overdose - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Drug Overdose, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020